New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)
Authors
Keywords
-
Journal
LEUKEMIA
Volume 28, Issue 3, Pages 525-542
Publisher
Springer Nature
Online
2013-11-20
DOI
10.1038/leu.2013.350
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02
- (2013) X. Leleu et al. BLOOD
- Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study
- (2013) A. Larocca et al. BLOOD
- PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma
- (2013) P. G. Richardson et al. BLOOD
- Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077
- (2013) Wolfram Pönisch et al. BRITISH JOURNAL OF HAEMATOLOGY
- In Vitro and In Vivo Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells
- (2013) D. Chauhan et al. CLINICAL CANCER RESEARCH
- Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients
- (2013) J. Rosenblatt et al. CLINICAL CANCER RESEARCH
- B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
- (2013) R. O. Carpenter et al. CLINICAL CANCER RESEARCH
- Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety
- (2013) A Z Badros et al. LEUKEMIA
- An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
- (2012) R. Vij et al. BLOOD
- A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
- (2012) D. S. Siegel et al. BLOOD
- Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib
- (2012) P. G. Richardson et al. BLOOD
- Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study
- (2012) S. Lentzsch et al. BLOOD
- Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy
- (2012) M. Chesi et al. BLOOD
- A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma
- (2012) D. M. Benson et al. BLOOD
- Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study
- (2012) Andrzej J. Jakubowiak et al. BRITISH JOURNAL OF HAEMATOLOGY
- A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma
- (2012) William Bensinger et al. BRITISH JOURNAL OF HAEMATOLOGY
- An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib
- (2012) Ravi Vij et al. BRITISH JOURNAL OF HAEMATOLOGY
- A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma
- (2012) M. Alsina et al. CLINICAL CANCER RESEARCH
- Phase I Trial of Vorinostat Combined With Bortezomib for the Treatment of Relapsing and/or Refractory Multiple Myeloma
- (2012) Donna M. Weber et al. Clinical Lymphoma Myeloma & Leukemia
- An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma
- (2012) Sundar Jagannath et al. Clinical Lymphoma Myeloma & Leukemia
- Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma
- (2012) Andrzej J. Jakubowiak et al. JOURNAL OF CLINICAL ONCOLOGY
- Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
- (2012) Sagar Lonial et al. JOURNAL OF CLINICAL ONCOLOGY
- Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
- (2012) A Lopez-Girona et al. LEUKEMIA
- Erratum: Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
- (2012) S K Kumar et al. LEUKEMIA
- Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma
- (2012) Jeffrey L. Wolf et al. LEUKEMIA & LYMPHOMA
- Therapeutic Evolution and the Challenge of Rational Medicine
- (2012) Jeremy A. Greene et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma
- (2011) Irene M. Ghobrial et al. AMERICAN JOURNAL OF HEMATOLOGY
- IMiD immunomodulatory compounds block C/EBP translation through eIF4E down-regulation resulting in inhibition of MM
- (2011) S. Li et al. BLOOD
- Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease
- (2011) M. Q. Lacy et al. BLOOD
- A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma
- (2011) S. J. Harrison et al. BLOOD
- A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
- (2011) J. A. Zonder et al. BLOOD
- RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5
- (2011) Y. X. Zhu et al. BLOOD
- Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
- (2011) Y. X. Zhu et al. BLOOD
- Bendamustine, Thalidomide and Dexamethasone is an effective salvage regimen for advanced stage multiple myeloma
- (2011) Elisabeth Grey-Davies et al. BRITISH JOURNAL OF HAEMATOLOGY
- Monoclonal antibodies in the treatment of multiple myeloma
- (2011) Paul G. Richardson et al. BRITISH JOURNAL OF HAEMATOLOGY
- Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease
- (2011) Karthik Ramasamy et al. BRITISH JOURNAL OF HAEMATOLOGY
- Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response
- (2011) Antonia Lopez-Girona et al. BRITISH JOURNAL OF HAEMATOLOGY
- Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study
- (2011) Paul G. Richardson et al. BRITISH JOURNAL OF HAEMATOLOGY
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial
- (2011) Paul G. Richardson et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Trial of Lenalidomide and CCI-779 in Patients With Relapsed Multiple Myeloma: Evidence for Lenalidomide–CCI-779 Interaction via P-Glycoprotein
- (2011) Craig C. Hofmeister et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine
- (2011) Jacalyn Rosenblatt et al. JOURNAL OF IMMUNOTHERAPY
- Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study
- (2011) Irene M Ghobrial et al. LANCET ONCOLOGY
- Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma
- (2011) P Moreau et al. LEUKEMIA
- Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma
- (2011) N W C J van de Donk et al. LEUKEMIA
- The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma
- (2011) S K Martin et al. LEUKEMIA
- Initial genome sequencing and analysis of multiple myeloma
- (2011) Michael A. Chapman et al. NATURE
- Multiple Myeloma
- (2011) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- New Insights into Therapeutic Targets in Myeloma
- (2011) K. C. Anderson Hematology-American Society of Hematology Education Program
- The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
- (2010) D. M. Benson et al. BLOOD
- Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma
- (2010) Ruben Niesvizky et al. CANCER
- Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-Hour Infusion Every Two Weeks Alone or with Dexamethasone in Relapsed and Refractory Multiple Myeloma
- (2010) M. V. Mateos et al. CLINICAL CANCER RESEARCH
- Dexamethasone Synergizes with Lenalidomide to Inhibit Multiple Myeloma Tumor Growth, But Reduces Lenalidomide-Induced Immunomodulation of T and NK Cell Function
- (2010) A. K. Gandhi et al. CURRENT CANCER DRUG TARGETS
- A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma
- (2010) M. Hussein et al. HAEMATOLOGICA
- The DAC system and associations with multiple myeloma
- (2010) Enrique M. Ocio et al. INVESTIGATIONAL NEW DRUGS
- Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
- (2010) M Q Lacy et al. LEUKEMIA
- Identification of a Primary Target of Thalidomide Teratogenicity
- (2010) T. Ito et al. SCIENCE
- A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma
- (2009) Monica Galli et al. ANNALS OF HEMATOLOGY
- Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic Mechanism
- (2009) L. Escoubet-Lozach et al. CANCER RESEARCH
- Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma
- (2009) A. Badros et al. CLINICAL CANCER RESEARCH
- A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies
- (2009) O. A. O'Connor et al. CLINICAL CANCER RESEARCH
- Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b
- (2009) K. Todoerti et al. HAEMATOLOGICA
- Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
- (2009) Martha Q. Lacy et al. JOURNAL OF CLINICAL ONCOLOGY
- Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047)
- (2009) Han-Jie Zhou et al. JOURNAL OF MEDICINAL CHEMISTRY
- Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma
- (2009) M A Dimopoulos et al. LEUKEMIA
- Dasatinib in relapsed or plateau-phase multiple myeloma
- (2009) Tanya M. Wildes et al. LEUKEMIA & LYMPHOMA
- Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma
- (2009) Sherif S. Farag et al. LEUKEMIA RESEARCH
- Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial
- (2008) Wolfram Pönisch et al. BRITISH JOURNAL OF HAEMATOLOGY
- Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation
- (2008) Matthew J. Streetly et al. BRITISH JOURNAL OF HAEMATOLOGY
- The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells
- (2008) Christine Galustian et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- HDAC family: What are the cancer relevant targets?
- (2008) Olaf Witt et al. CANCER LETTERS
- Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells
- (2008) L. Wu et al. CLINICAL CANCER RESEARCH
- Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti–Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma
- (2008) Martha Q. Lacy et al. JOURNAL OF CLINICAL ONCOLOGY
- New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings
- (2008) Enrique M Ocio et al. LANCET ONCOLOGY
- Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma
- (2008) Paul Richardson et al. LEUKEMIA & LYMPHOMA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search